ClinicalTrials.gg
CompletedNCT00640276ProPitUpdated Mar 30, 2012

Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome

A Phase 4 interventional study of pitavastatin and Lifestyle Modification in Hypercholesterolemia and Metabolic Syndrome, sponsored by JW Pharmaceutical. Completed at 2 sites in Korea, Republic of. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-03-30.

Sponsored by JW Pharmaceutical · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.

Enrollment
12th of 19
187 · median 200
Started
2008
with 2 others
Phase 4
8 of 19
none open now
Registered
11th of 19
by date
Lead sponsor
4 of 19
JW Pharmaceutical

Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one is the 12th largest by enrollment, is one of 3 that started in 2008, is one of 8 in phase 4, and was the 11th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About pitavastatin

pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing pitavastatin in Hypercholesterolemia as a file.
02

Study summary

We will identify the influence of long-term treatment of Pitavastatin compared to non-treatment control group on the metabolic syndrome by evaluation of a change of metabolic syndrome component score. And we will additionally observe the changes of CVD risk factors like lipid profile, abdominal fat, insulin resistance and so on.

03

Conditions studied

  • Hypercholesterolemia
  • Metabolic Syndrome

Keywords

  • pitavastatin
  • metabolic syndrome
  • metabolic syndrome risk score
  • hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 18 and 75
  • Patients with LDL ≥ 100mg/dL
  • Patients with metabolic syndrome

    1. IFG: Fasting glucose ≥ 100mg/dL
    2. Abdominal Obesity: Waist circumference: men≥90cm,women≥85cm
    3. 1 or more of the following

      1. Triglyceride ≥ 150mg/dL
      2. HDL-C: men \< 40mg/dL, women \< 50mg/dL
      3. Blood pressure: SBP ≥ 130mmHg or DBP ≥ 85mmHg or subject receiving anti-hypertensive treatment

Exclusion criteria

Exclusion Criteria:

  • uncontrolled hypertension (DBP ≥ 95mmHg)
  • taking diabetic drugs or with > 8%
  • LDL ≥ 190mg/dL or Triglyceride ≥ 400mg/dL
  • coronary heart disease or other diseases caused by artherosclerosis
  • within 6 months
  • Serum creatinine ≥ 2.0mg/dL
  • or AST ≥ *2.5
  • CPK ≥ ULN*2
  • hypothyroidism
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
187 participants (actual)

Study arms

  • Active comparator
    T

    Lifestyle modification + active drug(Pitavastatin)

    Drug: pitavastatin

  • Other
    C

    Lifestyle Modification

    Behavioral: Lifestyle Modification

Interventions

  • Pitavastatin 2mg daily once

    Also known as: Livaro

  • BehavioralLifestyle Modification

    conducting mainly exercises and diet

06

What researchers measure

Primary outcomes

  1. A change of metabolic syndrome risk component

    Time frame: 48week

Secondary outcomes

  1. Changes of cardiometabolic profiles : lipid profiles, hs-CRP, adiponectin, HMW adiponectin

    Time frame: 48week

  2. Changes of abdominal visceral fat

    Time frame: 48week

  3. Changes of insulin resistance : OGTT(75g), HOMA

    Time frame: 48week

07

Study locations

2 sites
  • Seoul National University Bundang Hospital
    Bundang-gu, Gyeonggi-do 463-707, Korea, Republic of
  • Hanyang Univ. Guri Hospital
    Guri-si, Gyeonggi-do 471-701, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Feb 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2008
First posted
Mar 21, 2008
Start
Apr 2008
Primary completionActual
Feb 2011
CompletionActual
Jun 2011
Last update
Mar 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00640276
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Mar 21, 2008
Start date
Apr 2008
Primary completion
Feb 2011
Completion
Jun 2011
Last update
Mar 30, 2012

Study contacts

Chang Beom Lee
study chair · Hanyang Univ. Guri Hospital
Hak Chul Jang
study chair · Seoul National University Bundang Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion